View ALL

FDA rejects new cholesterol med

The U.S. Food and Drug Administration (FDA) has rejected an experimental cholesterol med, saying the agency needs more information about the drug. The med, called Cordaptive (MK-0524A), lowers bad cholesterol and raises good cholesterol and has been recommended for approval in Europe. Drugmaker Merck says it plans to resubmit the drug's application with the FDA's required information, this time under the brand name Tredaptive.

(HealthDay News) UPDATED 04/30/2008
Click here to read the full story

Helpful?

Navigation

Member Picks

Chronic pain harms the brain
View Full Story

Three vitamin supplements reflux sufferers may need
View Full Story

Research your meds on the Treatments tab
View Full Story

Caffeine could spell trouble for diabetics
View Full Story

MedTrackAlert is a consumer health information company dedicated to helping people better understand the benefits and risks of prescription medications. We provide our members with important, time-sensitive news to keep them aware of new advances, adverse drug interactions, and potential dangers related to the medications they take. With trusted prescription news and condition coverage we can help you maintain collaboration with your doctors in the management of your health. More About Us.

Copyright © 2008 The HealthCentral Network, Inc. All rights reserved. All brands listed are the trademarks of their respective owners and are not trademarks of The HealthCentral Network, Inc. 1655 Fort Myer Drive, Suite 400, Arlington, Virginia 22209.

Disclaimer: The information provided is not intended to be medical advice. You should contact your physician about your medication and health care. HealthCentral Network, Inc. is not responsible for content provided by third-party Web sites. We will always respect your privacy.

Advertise with Us
Email Policy